We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · September 20, 2021

Gemcitabine With or Without Ramucirumab as Second-Line Treatment for Malignant Pleural Mesothelioma

The Lancet Oncology


Additional Info

The Lancet Oncology
Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial
Lancet Oncol 2021 Sep 06;[EPub Ahead of Print], C Pinto, PA Zucali, M Pagano, F Grosso, G Pasello, MC Garassino, M Tiseo, H Soto Parra, F Grossi, F Cappuzzo, F de Marinis, P Pedrazzoli, M Bonomi, L Gianoncelli, M Perrino, A Santoro, F Zanelli, C Bonelli, A Maconi, S Frega, E Gervasi, L Boni, GL Ceresoli

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading